1. Joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) & Committee on Toxicity (COT) on establishing a provisional acceptable daily intake (ADI) for pure form (≥98%) cannabidiol (CBD) in foods, based on new evidence;Advisory Committee on Novel Foods and Processes (ACNFP),2023
2. Committee On Mutagenicity Of Chemicals In Food, Consumer Products And The Environment, (MUT/MIN/2020/1), 2020; https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/967784/Final_COM_mins_February_2020.pdf#:~:text=The%20Committee%20on%20the%20Toxicity%20of%20Chemicals%20in,requested%20a%20COM%20view%20of%20the%20genotoxicity%20data.
3. de Jong BG, 2020 [unpublished]. Prepared by Charles River Laboratories Den Bosch B.V., DD ‘s Hertogenbosch, The Netherlands for Chanelle McCoy CBD Ltd., Loughrea, Galway, Ireland. Study Title: Cannabidiol: in vitro mammalian cell micronucleus test. Confidential. (Test Facility Study No. 20203946).
4. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome [GWPCARE1 Part A Study Group];O. Devinsky;Neurology,2018
5. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements;OJ L 183,2002